Five-year overall survival update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients with BRAF V600–mutant unresectable or metastatic melanoma

Home / Abstract / Five-year overall survival update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients with BRAF V600–mutant unresectable or metastatic melanoma